NCT00295269 is a Phase 3 clinical trial of Mythylprednisolone in Acute Respiratory Distress Syndrome, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Who is sponsoring NCT00295269?

NCT00295269 is sponsored by National Heart, Lung, and Blood Institute (NHLBI).

What drugs are being tested in NCT00295269?

Interventions in NCT00295269: Mythylprednisolone.

What condition does NCT00295269 study?

NCT00295269 studies Acute Respiratory Distress Syndrome, Lung Diseases.

Is NCT00295269 still recruiting?

NCT00295269 is currently completed. Last updated 8 May 2006.

Last reviewed 2006-05-08 · How we verify

NCT00295269

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Late Steroid Rescue Study (LaSRS): The Efficacy of Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome

Completed Phase 3 Last updated 8 May 2006

What this trial tests

Phase 3 trial testing Mythylprednisolone in Acute Respiratory Distress Syndrome in 200 participants. Completed in 1 September 2005.

Timeline

1 March 1997

1 September 2005

Quick facts

Lead sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	1 March 1997
Estimated completion	1 September 2005

Drugs / interventions tested

Mythylprednisolone — full drug profile →

Conditions studied

Acute Respiratory Distress Syndrome — all drugs for Acute Respiratory Distress Syndrome →
Lung Diseases — all drugs for Lung Diseases →

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

13 and older, any sex, with Acute Respiratory Distress Syndrome or Lung Diseases. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mortality rates (measured at time of hospital discharge or 60 days after study entry)

Sponsor's own description

The purpose of this study is to assess innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome.
Steinberg KP, Hudson LD, Goodman RB, Hough CL, et al · · 2006 · cited 956× · PMID 16625008 · DOI 10.1056/nejmoa051693
Pharmacological agents for adults with acute respiratory distress syndrome.
Lewis SR, Pritchard MW, Thomas CM, Smith AF. · · 2019 · cited 128× · PMID 31334568 · DOI 10.1002/14651858.cd004477.pub3
Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics.
Pokharel MD, Garcia-Flores A, Marciano D, Franco MC, et al · · 2024 · cited 73× · PMID 38295575 · DOI 10.1016/j.redox.2024.103049
Acute Respiratory Distress Syndrome and COVID-19: A Literature Review.
Hussain M, Khurram Syed S, Fatima M, Shaukat S, et al · · 2021 · cited 38× · PMID 34992415 · DOI 10.2147/jir.s334043
Steroids in late ARDS?
Wajanaponsan N, Reade MC, Milbrandt EB. · · 2007 · cited 11× · PMID 17666114 · DOI 10.1186/cc5954

Verify or expand the search:

Other recruiting trials for Acute Respiratory Distress Syndrome

Currently open trials in the same condition.

NCT07284888 — Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry- · recruiting
NCT07289711 — Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter C · recruiting
NCT07326215 — A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+ · NA · recruiting
NCT06919484 — The Physiological Effect of RCexp on Ventilation/Perfusion Distribution · recruiting
NCT07126964 — Extended Prone Positioning for Intubated ARDS · NA · recruiting

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00295269 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
Last refreshed: 8 May 2006

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00295269.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing